Showing results (11-20 of 379) with videos related to
Sort By:
Pageof 38
ESMO Open|June 25, 2019
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and managementLucie Heinzerling, Thomas K Eigentler, Michael Fluck, et al.Future Oncology (London, England)|February 17, 2022
Tebentafusp for the treatment of metastatic uveal melanomaTimo E Schank, Jessica C HasselClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2022
Autoantibodies as Predictors for Clinical Outcome and Toxicity for ImmunotherapyJessica C Hassel, Jason J LukeCancers|July 27, 2019
Immunotherapies for the Treatment of Uveal Melanoma-History and FutureTimo E Schank, Jessica C HasselFrontiers in Immunology|July 14, 2018
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and BeyondKristina Buder-Bakhaya, Jessica C HasselCancers|July 14, 2023
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint InhibitionJessica C Hassel, Lisa Zimmer, Thomas Sickmann, et al.Cancers|December 11, 2025
Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448Jessica C Hassel, Lisa Zimmer, Thomas Sickmann, et al.European Journal of Cancer (Oxford, England : 1990)|November 5, 2013
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsSimone M Goldinger, Lisa Zimmer, Carsten Schulz, et al.Breast Care (Basel, Switzerland)|December 5, 2019
Prophylaxis and Management of Skin ToxicitiesMartin Salzmann, Frederik Marmé, Jessica C HasselOncology Research and Treatment|June 5, 2016
Immunotherapy of MelanomaCarolin Bender, Jessica C Hassel, Alexander EnkPageof 38